The Benefits of Lorlatinib for ALK+ NSCLC: CROWN Update

Opinion
Video

This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial.

Video content above is prompted by the following:

  • Can you summarize the clinical evidence supporting lorlatinib use in the first-line treatment of ALK+ metastatic NSCLC?
  • Could you highlight the primary efficacy outcomes from the phase 3 CROWN trial?
Recent Videos
4 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Zipalertinib Meets Primary ORR End Point in EGFR exon 20 NSCLC

Tim Cortese
January 29th 2025
Article

Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC

Roman Fabbricatore
January 22nd 2025
Article

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Anlotinib Prolongs EGFR-TKI Clinical Benefit in Advanced NSCLC

Roman Fabbricatore
January 21st 2025
Article

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.